Carclo plc's audited results for the year to 31 March 2026 showed underlying operating profit up more than a quarter even as revenue fell, with net debt and pension liabilities both easing. Shares dipped on the day despite the turnaround signal.

Carclo published audited results for the year ended 31 March 2026 on 1 July 2026, confirming trading broadly as flagged in an April 2026 update. Underlying operating profit rose to £12.6 million from £9.8 million, while profit before tax nearly doubled to £4.8 million from £2.7 million. Revenue fell to £114.2 million from £121.2 million, which the company attributed to portfolio rebalancing and the completion of certain customer design-and-engineering projects in the United States. Shares fell roughly 4% on the day as investors weighed the revenue decline and rising net debt against the margin gains.

Company Overview and Business Model

Carclo plc is a UK-headquartered precision engineering group listed on the Main Market of the London Stock Exchange. It designs and manufactures high-precision components and assemblies for regulated end markets, organised broadly around two divisions: a larger Manufacturing Solutions and Design & Engineering business (commonly referred to by its historical Carclo Technical Plastics, or CTP, branding) serving life sciences, and a smaller Speciality division covering aerospace, defence and specialist machining. Its stated market focus spans life science (in-vitro diagnostics, medical devices, drug delivery and pharmaceutical packaging), aerospace and defence, and safety and security, with manufacturing across the UK, continental Europe, the US and China.

Inside the Latest Announcement

The FY26 results showed the CTP-type division (Manufacturing Solutions plus Design & Engineering) generating revenue of £98.2 million, down 8.2%, at a 15.4% operating margin; Design & Engineering undershot on weaker US customer activity, while China "outperformed expectations on both revenue and margin." The smaller Speciality division grew revenue 12.5% to £16.0 million at a 22.4% margin, with aerospace reporting record orders for a third consecutive year.

Most Recent Financial Performance

For the twelve months to 31 March 2026 (audited), profit after tax more than tripled to £2.7 million from £0.9 million, with earnings per share rising to 3.6p from 1.2p. Underlying EBITDA improved to £18.6 million from £16.4 million. The company said it had achieved its medium-term Return on Sales target of 10% (delivering 11.0%) and Return on Capital Employed target of 25% (delivering 29.1%) ahead of schedule. No dividend was proposed; management said cash would instead fund the growth strategy.

Cash, Debt, Pension and Funding

Group net debt rose to £23.9 million at 31 March 2026 from £19.2 million, with cash falling to £5.8 million from £10.7 million, reflecting reinvestment and higher working capital even as profitability improved. This follows a period of substantial deleveraging: net debt (including leases) had fallen to roughly £19.3 million at the end of FY25 from £29.5 million the year before, linked to an April 2025 refinancing with BZ Commercial Finance DAC comprising a £27 million term loan and a £9 million revolving credit facility.

On pensions, an April 2025 valuation disclosed a triennial technical provisions deficit of £64.5 million as at 31 March 2024 (down from £82.8 million in 2021), funded by a £5.1 million lump sum and £3.5 million annual contributions. By 31 March 2026 that deficit had narrowed to £52.9 million, while the IAS 19 accounting net pension liability stood at £46.8 million, down from £51.7 million.

Separately, Carclo's shares were briefly suspended from 1 August to 1 September 2025 after auditor Forvis Mazars sought more time to complete the FY25 audit; the auditor later resigned "for commercial reasons" and HaysMac LLP was appointed for FY26 — a resolved episode, but one illustrating a reporting-timeliness risk.

Operational and Commercial Strategy

Alongside the FY26 results, Carclo introduced "Precision 2030," a five-year strategic plan targeting organic revenue growth at a compound annual rate of more than 8% across the plan period, net debt below 0.5 times EBITDA by 2030, and maintenance of the 10% Return on Sales and 25% ROCE minimums already achieved. Management described the strategy as resting on two pillars: "Expand," meaning deeper relationships with existing customers and moves into adjacent markets such as drug delivery and pharmaceutical packaging, and "Innovate," covering proprietary technology, materials and product development. A July 2025 renewal of a major customer contract for a further five years, covering "a significant portion" of group revenue, reinforces medium-term visibility but underscores customer-concentration risk.

Industry Context

Carclo operates in precision plastics and metal manufacturing for regulated end markets — principally medical devices and in-vitro diagnostics, alongside aerospace and defence. Diagnostics volumes are sensitive to seasonal respiratory illness, and Carclo flagged softer demand tied to a weaker virus season as temporary. Aerospace, by contrast, has benefited from sustained commercial and defence build rates, consistent with its record order intake for three consecutive years.

Growth Catalysts

  • Delivery against the Precision 2030 targets, beginning with FY27 trading
  • Progress in adjacent life-sciences markets such as drug delivery and pharmaceutical packaging
  • Continued aerospace order strength
  • Net debt reduction toward the 0.5x EBITDA goal, easing refinancing risk

Material Risks

  • The defined-benefit pension scheme remains a sizeable long-term liability relative to Carclo's balance sheet and market value
  • Refinancing risk given reliance on the BZ Commercial Finance facilities and the margin premium attached to them
  • Customer concentration, with a small number of major contracts representing a significant share of revenue
  • General liquidity and volatility of a small-cap stock, illustrated by both the 2025 suspension episode and the roughly 4% single-day share price move

Conclusion

Carclo's FY26 audited results confirm a group that has restored profitability and hit medium-term margin and returns targets ahead of schedule, while revenue and net debt both moved in less favourable directions over the same period. The Precision 2030 plan gives a framework against which to judge the next phase, but its targets are guidance, not guarantees. With the pension scheme, refinancing terms and customer concentration still live, FY27 trading updates will be the clearest test of whether the turnaround extends into sustained growth.